Literature DB >> 15183599

Treatment and response in refractory depression: results from a specialist affective disorders service.

N Kennedy1, E S Paykel.   

Abstract

BACKGROUND: The best treatment approaches for chronic severe refractory depression remain uncertain. This study aimed to identify short-term outcome and most successful somatic treatments of severe refractory depressives referred to an affective disorders service.
METHODS: Patients with chronic refractory depression referred to a specialist affective disorders service over a 10-year period were studied. Using detailed case records of the index episode, courses of treatment and outcome were examined.
RESULTS: Patients were predominantly middle-aged females with few prior episodes but long index episodes. Patients received higher antidepressant doses and more combinations on the specialist service. Very-high-dose antidepressants (tricyclics, velafaxine or tricyclic--MAOI combinations), usually augmented with lithium and often combined with ECT, were the most effective somatic treatments. Most subjects improved substantially, but few reached premorbid levels. LIMITATIONS: The study was retrospective. Treatment courses were sequential rather than random.
CONCLUSIONS: Refractory depression is responsive to vigorous somatic therapy, although most patients continue with some symptoms.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15183599     DOI: 10.1016/S0165-0327(03)00192-7

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  2 in total

1.  Predictors of bipolar disorder risk among patients currently treated for major depression.

Authors:  Joseph R Calabrese; David J Muzina; David E Kemp; Gary S Sachs; Mark A Frye; Thomas R Thompson; David Klingman; Michael L Reed; Robert M A Hirschfeld
Journal:  MedGenMed       Date:  2006-08-15

2.  Lithium: the pharmacodynamic actions of the amazing ion.

Authors:  Kayleigh M Brown; Derek K Tracy
Journal:  Ther Adv Psychopharmacol       Date:  2013-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.